Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET

Company Overview - Aquestive Therapeutics, Inc. is a pharmaceutical company focused on advancing medicines to improve patients' lives through innovative science and delivery technologies [4] - The company is developing orally administered products to deliver complex molecules, providing alternatives to invasive therapies [4] - Currently, Aquestive has four commercialized products marketed by its licensees in the U.S. and globally, and it is the exclusive manufacturer of these products [4] Recent Developments - The company will report its first-quarter results for the period ended March 31, 2025, and provide business updates on May 12, 2025, after market close [1] - A conference call for investors is scheduled for May 13, 2025, at 8:00 a.m. ET, with a live webcast available on the company's website [2] Product Pipeline - Aquestive is advancing a late-stage proprietary product candidate for treating severe allergic reactions, including anaphylaxis [4] - The company is also developing an earlier-stage epinephrine prodrug topical gel for dermatological conditions such as alopecia areata [4]